- Fit to be tried: Rationale's lacking in I-O attempts but personalized ploy may win
- Advocates tell their stories, struggles, to inspire a patient-centric culture
- NIH grants critical to de-risk programs, attract more capital
- Novartis shoots a hoop with Ilaris in cardiovascular outcomes study
- Aligned interests bond ex-U.S. investors and U.S...
SAN DIEGO – The Biotechnology Innovation Organization's (BIO) International Convention, which runs June 19-22, returns to the thriving southern California biotechnology hub of San Diego just three years since it last hosted the giant event in 2014. The meeting allows a chance for industry leaders to take stock of progress that has been made to date. Overall, it appears that the report card is good. The biopharmaceutical sector, despite some major challenges in the intervening years, is continuing to generate support from investors, and that is reflected by the 10 percent growth in the BioWorld Biopharmaceutical Index in that period, and the almost $140 billion collectively raised by public and private companies to fuel their product development activities.
SAN DIEGO – Nobody wants to get old. Health declines, disease increases and insurance costs skyrocket. But what if researchers could slow the process at the cellular level, reverting stem cells to their youthful state, or clearing senescent cells, a hallmark of advanced years?
Two companies working in the space presented their research at the BIO convention during a session titled "Reimagine Old Age: New Frontiers in the Science of Aging."
The aging process involves a loss of homeostasis, with messy DNA and reduced gene expression.READ MORE »
- Stem cell treatment shows promise in severe spina bifida »
- Development to dementia, stem cells help understand the brain »
- Putting the liver to work makes quick bispecifics »
- Mitochondrial dysfunction leads to motor problems in fly model of Parkinson's »
- Viable new pain relief target identified in Australia »
- NGS maybe, sort of, sometimes clinic-ready »
- Statins overcome osteosarcoma metastasis and stemness »
- Potential therapeutic target pathway is identified in ALS »
- Chromatin state plays role in T cells' will to fight »
- No choice, no free marketJune 20, 2017 | 6:35 PM | Posted by: Mari Serebrov
- Poverty, politics and preventable disease: Blurring the lines between truth and fiction in BioWorld’s 11th annual Summer Reading ListJune 01, 2017 | 4:13 PM | Posted by: Marie Powers
- Scientists don’t do politics … until nowApril 24, 2017 | 12:03 PM | Posted by: Nuala Moran
- Myth busters take on drug prices, or do they? April 04, 2017 | 1:35 AM | Posted by: Mari Serebrov
- Is ‘what the patient pays’ the right barometer for pricing drugs?January 26, 2017 | 5:08 PM | Posted by: Mari Serebrov
Partners in Focus
